Polycystic ovary syndrome, obesity and reproductive implications

Women's Health

Volumn 5, Issue 5, 2009, Pages 529-542

  Hirschberg, Angelica Lindén ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Bariatric surgery; Fertility; Lifestyle modification; Metformin; Obesity; Polycystic ovary syndrome; Pregnancy outcome

Indexed keywords

ANDROGEN; CHOLECYSTOKININ; CLOMIFENE; GLUCOSE; INSULIN; LUTEINIZING HORMONE; METFORMIN; PLACEBO; SEX HORMONE BINDING GLOBULIN; SIBUTRAMINE; SOMATOMEDIN BINDING PROTEIN 1; TESTOSTERONE; TETRAHYDROLIPSTATIN;

ANOVULATION; BARIATRIC SURGERY; BODY WEIGHT; CLINICAL TRIAL; DIET THERAPY; DISEASE ASSOCIATION; EXERCISE; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HEALTH PROGRAM; HUMAN; HYPERANDROGENISM; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LOW CARBOHYDRATE DIET; MATERNAL HYPERTENSION; METABOLIC RATE; OBESITY; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PREECLAMPSIA; PREGNANCY; PREGNANCY DIABETES MELLITUS; PREGNANCY OUTCOME; PREMATURITY; PROTEIN DIET; REPRODUCTION; REVIEW; SPONTANEOUS ABORTION; WEIGHT GAIN; WEIGHT REDUCTION; COMPLICATION; GONADAL DISEASE; INFERTILITY, FEMALE; OVERWEIGHT; POLYCYSTIC OVARY SYNDROME;

ANOVULATION; FEMALE; HUMANS; INFERTILITY, FEMALE; INSULIN RESISTANCE; OBESITY; OVERWEIGHT; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PREGNANCY OUTCOME; VIRILISM; WEIGHT LOSS;

EID: 69849095430     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.09.39     Document Type: Review

References (104)

1. Ehrmann DA: Polycystic ovary syndrome. N. Engl. J. Med. 352, 12 (2005).
2. Balen AH, Conway GS, Kaltsas G et al.: Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum. Reprod. 10, 2107-2111 (1995).
3. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO: The prevalence and features of the polycystic ovary syndrome in an unselected population. J. Clin. Endocrinol. Metab. 89, 2745-2749 (2004).
4. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril. 81, 19-25 (2004).
5. Azziz R, Carmina E, Dewailly D et al.: Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J. Clin. Endocrinol. Metab. 91, 4237-4245 (2006).
6. Stein IF, Leventhal ML: Amenorrhea associated with bilateral polycystic ovaries. Am. J. Obstet. Gynecol. 29, 181-191 (1935).
7. Frank S: Symposium: Diet, nutrition and exercise in reproduction. Genetic and environmental origins of obesity relevant to reproduction. Reprod. Biomed. Online. 12, 526-531 (2006).
8. Legro RS, Driscoll D, Strauss JF 3rd, Fox J, Dunaif A: Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc. Natl Acad. Sci. USA 95, 14956-14960 (1998).
9. Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI: Heritability of polycystic ovary syndrome in a Dutch twin-family study. J. Clin. Endocrinol. Metab. 91, 2100-2104 (2005).
10. Abbott DH, Foong SC, Barnett DK, Dumesic DA: Nonhuman primates contribute unique understanding to anovuatory infertility in women. ILAR J. 45, 116-131 (2004).
11. Watve MG, Yajnil CS: Evolutionary origins of insulin resistance: a behavioral switch hypothesis. BMC Evol. Biol. 7, 61 (2007).
12. Escobar-Morreale HF, San Millán JL: Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol. Metab. 18, 266-272 (2007).
13. Nelson VL, Legro, RS, Strauss JF 3rd, McAllister JM: Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol. Endocrinol. 13, 946-957 (1999).
14. Wood JR, Ho CK, Nelson-Degrave VL, McAllister JM, Strauss JF 3rd: The molecular signature of polycystic ovary syndrome (PCOS) theca cells defines by gene expression profiling. J. Reprod. Immunol. 63, 51-60 (2004).
15. Pastor CL, Griffin-Korf ML, Aloi JA, Evans WS, Marshall JC: Polycystic ovary syndrome: evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J. Clin. Endocrinol. Metab. 83, 582-590 (1998).
16. Webber LJ, Stubbs S, Stark J et al.: Formation and early development of follicles in the polycystic ovary. Lancet 362, 1017-1021 (2003).
17. Dunaif A: Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr. Rev. 18, 774-800 (1997).
18. Dunaif A, Wu X, Lee A, Diamanti-Kandarakis E: Defects in insulin receptor signaling in vivo in the polycystic ovary syndro. Am. J. Physiol. Endocrinol. Metab. 281, E392-E399 (2001).
19. Diamanti-Kandarakis E, Papavasiliou AG: Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol. Med. 12, 324-332 (2006).
20. Bremer AA, Miller WL: The serine phosphorylatioin hypothesis of polycystic ovary syndrome: a unifying mechanism for hyperandrogenemia and insulin resistance. Fertil. Steril. 89, 1039-1048 (2008).
21. Poretsky L: On the paradox of insulin-induced hyperandrogenism in insulin-resistant states. Endocr. Rev. 12, 3-13 (1991).
22. Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC: The insulin-related ovarian regulatory system in health and disease. Endocr. Rev. 20, 535-582 (1999).
23. Nestler JE, Powers LP, Matt DW et al.: A direct effects of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 72, 83-89 (1991).
24. Ek I, Arner P, Rydén M et al.: A unique defect in the regulation of visceral fat cell lipolysis in the polycystic ovary syndrome as an early link to insulin resistance. Diabetes 51, 484-492 (2002).
25. Rincon J, Holmäng A, Wahlström EO et al.: Mechanisms behind insulin resistance in rat skeletal muscle after oophorectomy and additional testosterone treatment. Diabetes 45, 615-121 (1996).
26. Zang H, Carlström K, Arner P, Hirschberg AL: Effects of treatment with testosterone alone or in combination with estrogen on insulin sensitivity in postmenopausal women. Fertil. Steril. 86, 136-144 (2006).
27. Zang H, Rydén M, Wåhlen K, Dahlman-Wrigth K, Arner P, Hirschberg AL: Effects of testosterone and estrogen treatment on lipolysis signaling pathways in sub-cutaneous adipose tissue of postmenopausal women. Fertil. Steril. 88, 100-106 (2007).
28. Carmina E, Bucchieri S, Esposito A et al.: Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J. Clin. Endocrinol. Metab. 92, 2500-2505 (2007).
29. Elbers JM, Giltary EJ, Teerlink T et al.: Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects. Clin. Endocrinol. 58, 562-571 (2003).
30. Legro RS, Kunselman AR, Doson WC, Dunaif A: Prevalence and predictors of risk for Type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J. Clin. Endocrinol. Metab. 84, 165-169 (1999).
31. Legro RS, Gnatuk CL, Kunselman AR, Dunaif A: Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J. Clin. Endocrinol. Metab. 90, 3236-3242 (2005).
32. Yildiz BO, Knochenhauer ES, Azziz R: Impact of obestity on the risk for polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 93, 162-168 (2008).
33. McCluskey S, Evans C, Lacey JH, Pearce JM, Jacobs H: Polycystic ovary syndrome and bulimia. Fertil. Steril. 55, 287-291 (1991).
34. Hirschberg AL, Naessén S, Stridsberg M, Byström B, Holte J: Impaired cholecystokinin secretion and disturbed appetite regulation in women with polycystic ovary syndrome. Gynecol. Endocrinol. 19, 79-87 (2004).
35. Moran LJ, Noakes M, Clifton PM et al.: Ghrelin and measures of satiety are altered in polycystic ovary syndrome but not differentially affected by diet composition. J. Clin. Endocrinol. Metab. 89, 3337-3344 (2004).
36. Rickenlund A, Carlström K, Ekblom B, Brismar T, von Schoultz B, Hirschberg AL: Hyperandrogenicity is an alternative mechanism underlying oligomenorrhea and amenorrhea in female athletes and may improve physical performance. Fertil. Steril. 79, 947-955 (2003).
37. Brassard M, AinMelk Y, Baillargeon JP: Basic infertility including polycystic ovary syndrome. Med. Clin. North Am. 92, 1163-1192 (2008).
38. Glueck CJ, Wang P, Goldenberg N, Sieve L: Pregnancy loss, polycystic ovary syndrome, thrombophilia, hypofibrinolysis, enoxaparin, metformin. Clin. Appl. Thromb. Hemost. 10, 323-334 (2004).
39. Cocksedge KA, Li TC, Saravelos SH, Metwally M: A reappraisal of the role of polycystic ovary syndrome in recurrent miscarriage. Reprod. Biomed. Online. 17, 151-161 (2008).
40. Giudice LC: Endometrium in PCOS: implantation and predisposition to endocrine CA. Best Pract. Res. Clin. Endocrinol. Metab. 20, 235-244 (2006).
41. Patel SS, Carr BR: Oocyte quality in adult polycystic ovary syndrome. Semin. Reprod. Med. 26, 196-203 (2008).
42. Hartz AJ, Barboriak PN, Wong A, Katayama KP, Rimm AA: The association of obesity with infertility and related menstrual abnormalities in women. Int. J. Obes. 3, 57-73 (1979).
43. Kiddy DS, Sharp PS, White DM et al.: Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clin. Endocrinol. 32, 213-220 (1990).
44. Pasquali R, Gambineri A, Pagotto U: The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG 113, 1148-1159 (2006).
45. Lobo RA, Gysler M, March CM, Goebelsmann U, Mishell DR Jr: Clinical and laboratory predictors of clomiphene response. Fertil. Steril. 37, 168-1974 (1982).
46. White DM, Polson DW, Kiddy D et al.: Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an ana lysis of 109 pregnancies in 225 women. J. Clin. Endocrinol. Metab. 81, 3821-3824 (1996).
47. Galtier-Dereure F, Pujol P, Dewailly D, Bringer J: Choice of stimulation in polycystic ovarian syndrome: the influence of obesity. Hum. Reprod. 12(Suppl. 1), 88-96 (1997).
48. Fedorcsák P, Dale PO, Storeng R, Tanbo T, Abyholm T: The impact of obesity and insulin resistance on the outcome of IVF or ICSI in women with polycystic ovarian syndrome. Hum. Reprod. 16, 1086-1091 (2001).
49. Fedorcsák P, Storeng R, Dale PO, Tanbo T, Abyholm T: Obesity is a risk factor for early pregnancy loss after IVF or ICSI. Acta Obstet. Gynecol. Scand. 79, 43-48 (2000).
50. McCormick B, Thomas M, Maxwell R, Williams D, Aubuchon M: Effects of polycystic ovarian syndrome on in vitro fertilization-embryo transfer outcomes are influenced by body mass index. Fertil. Steril. 90, 2304-2309 (2008).
51. Jungheim ES, Lanzendorf SE, Odem RR, Moley KH, Chang AS, Ratts VS: Morbid obesity is associated with lower clinical pregnancy rates after in vitro fertilization in women with polycystic ovary syndrome. Fertil. Steril. 92(1), 256-261 (2009).
52. Holte J, Bergh T, Gennarelli G, Wide L: The independent effects of polycystic ovary syndrome and obesity on serum contraceptions of gonadotrophins and sex steroids in premenopausal women. Clin. Endocrinol. 41, 473-181 (1994).
53. Morales AJ, Laughlin GA, Bützow T, Maheshwari H, Baumann G, Yen SS: Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J. Clin. Endocrinol. Metab. 81, 2854-2964 (1996).
54. Pausquali R, Pelusi C, Genghini S, Cacciari M, Gambineri A: Obesity and reproductive disorders in women. Hum. Reprod. Update 9, 359-372 (2003).
55. Hamilton-Fairley D, Kiddy D, Watson H, Paterson C, Franks S: Association of moderate obesity with a poor pregnancy outcome in women with polycystic ovary syndrome treated with low dose gonadotrophin. Br. J. Obstet. Gynaecol. 99, 129-131 (1992).
56. Al-Azemi M, Omu FE, Omu AE: The effect of obestiy on the outcome of infertility managment in women with polycystic ovary syndrome. Arch. Gynecol. Obstet. 270, 205-210 (2004).
57. Wang JX, Davies MJ, Norman RJ: Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment. Hum. Reprod. 16, 2606-2609 (2001).
58. Metwally M, Ong KJ, Ledger WL, Li TC: Does high body mass index increase the risk of miscarriage after spontaneous and assisted conception? A meta-analysis of the evidence. Fertil. Steril. 90, 714-726 (2008).
59. Glueck CJ, Wang P, Fontaine RN, Sieve-Smith L, Tracy T, Moore SK: Plasminogen activator inhibitor acitivity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism 48, 1589-1995 (1999).
60. Glueck CJ, Wang P, Bornovali S, Goldenberg N, Sieve L: Polycystic ovary syndrome, the G1691A factor V Leiden mutation, and plasminogen activator inhibitor activity: associations with reccurent pregnancy loss. Metabolism 52, 1627-1632 (2003).
61. Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS: A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum. Reprod. Update 12, 673-683 (2006).
62. Holte J, Gennarelli G, Wide L, Lithell H, Berne C: High prevalence of polycystic ovaries and associated clinical, endocrine, and metabolic features in women with previous gestational diabetes meilitus. J. Clin. Endocrinol. Metab. 83, 1143-1150 (1998).
63. Levran D, Shoham Z, Habib D, Greewald M, Nebel L, Mashiach S: Glucose tolerance in pregnant women following treatment for sterility. Int. J Fertil. 35, 157-159 (1990).
64. Radon PA, McMahon MJ, Meyer WR: Impaired glucose tolerance in pregnant women with polycystic ovary syndrome. Obstet. Gynecol. 94, 194-197 (1999).
65. Vollenhoven B, Clark S, Kovacs G, Burger H, Healy D: Prevalence of gestational diabetes mellitus in polycystic ovarian syndrome (PCOS) patients pregnant after ovulation induction with gonadotrophins. Aust. NZ J. Obstet. Gynaecol. 40, 54-58 (2000).
66. Sir-Petermann T, Hitchsfeld C, Maliqueo M et al.: Birth weight in offspring of mothers with polycystic ovarian syndrome. Hum. Reprod. 20, 2122-2126 (2005).
67. Mikola M, Hiilesmaa V, Halttunen M, Suhonen L, Tiitinen A: Obstetric outcome in women with polycystic ovarian syndrome (PCOS). Hum. Reprod. 16, 226-229 (2001).
68. Wolf M, Sandler L, Munoz K, Hsu K, Ecker JL, Thadhani R: First trimester insulin resistance and subsequent preeclampsia: a prospective study. J. Clin. Endocrinol. Metab. 87, 1563-1568 (2002).
69. Urman B, Sarac E, Dogan L, Gurgan T: Pregnancy in infertile PCOD patients. Complications and outcome. J. Reprod. Med. 42, 501-505 (1997).
70. Fridström M, Nisell H, Sjöblom P, Hillensjö T: Are women with polycystic ovary syndrome at an increased risk of pregnancy-induced hypertension and/or preeclampsia? Hypertens. Pregnancy 18, 73-80 (1999).
71. Bjercke S, Dale PO, Tanbo T, Storeng R, Ertzeid G, Abyholm T: Impact of insulin resistance on pregnancy complications and outcome in women with polycystic ovary syndrome. Gynecol. Obstet. Invest. 54, 94-98 (2002).
72. Turhan NO, Seckin NC, Aybar F, Inegol I: Assessment of glucose tolerance and pregnancy outcome of polycystic ovary patients. Int. J. Gynaecol. Obstet. 81, 163-168 (2003).
73. Haakova L, Cibula D, Rezabek K, Hill M, Fanta M, Zivny J: Pregnancy outcome in women with PCOS and in controls matched by age and weight. Hum. Reprod. 18, 1438-1441 (2003).
74. Huber-Buchholz MM, Carey DGP, Norman RJ: Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J. Clin. Endocrinol. Metab. 84, 1470-1474 (1999).
75. Moran LJ, Naokes M, Clifton PM, Tomlinson L, Galletly C, Norman RJ: Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 88, 812-819 (2003).
76. Hoeger KM, Kochman L, Wixom N, Craig K, Miller RK, Guzick DS: A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil. Steril. 82, 421-429 (2004).
77. Palomba S, Giallauria F, Falbo A et al.: Structured exercise training programme versus hypocaloric hyperproteic diet in obese polycystic ovary syndrome patients with anovulatory infertility: a 24-week pilot study. Hum. Reprod. 23, 642-650 (2008).
78. Thomson RL, Buckley JD, Noakes M, Clifton PM, Norman RJ, Brinkworth GD: The effect of a hypocaloric diet with and without exercise training on body composition, cardiometabolic risk profile, and reproductive function in overweight and obese women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 93, 3373-3380 (2008).
79. Moran LJ, Pasquali R, Teede HJ, Hoeger KM, Norman RJ: Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil. Steril. (2008) (Epub ahead of print).
80. Stamets K, Taylor DS, Kunselman A, Demers LM, Pelkman CL, Legro RS: A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome. Fertil. Steril. 81, 630-637 (2004).
81. Sacks FM, Bray GA, Carey VJ et al.: Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N. Engl. J. Med. 360, 859-873 (2009).
82. Vigorito C, Giallauria F, Palomba S et al.: Beneficial effects of a three-month structured exercise training program on cardiopulmonary functional capacity in young women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 92, 1379-1384 (2007).
83. Palomba S, Falbo A, Zullo F, Orio F Jr: Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr. Rev. 30(1), 1-50 (2009).
84. Pasquali R, Gambineri A, Biscotti D et al.: Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 85, 2767-2774 (2000).
85. Moghetti P, Castello R, Negri C et al.: Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6 month trial, followed by open, long-term clinical evaluation. J. Clin. Endocrinol. Metab. 85, 139-146 (2000).
86. Maciel GA, Soares Junior JM, Alves da Motta EL, Abi Haidar M, de Lima GR, Baracat EC: Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil. Steril. 81, 355-360 (2004).
87. Lord JM, Flight IH, Norman RJ: Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 327, 951-953 (2003).
88. Legro RS, Barnhart HX, Schlaff WD et al.: Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N. Engl. J. Med. 356, 551-566 (2007).
89. Vanky E, Salvesen KA, Heimstad R, Fougner KJ, Romundstad P, Carlsen SM: Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. Hum. Reprod. 19, 1734-1740 (2004).
90. Glueck CJ, Goldenberg N, Wang P, Loftspring M, Sherman A: Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy. Hum. Reprod. 19, 510-521 (2004).
91. Thatcher SS, Jackson EM: Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin. Fertil. Steril. 85, 1002-1009 (2006).
92. Zolghadri J, Tavana Z, Kazerooni T, Soveid M, Taghieh M: Relationship between abnormal glucose tolerance test and history of previous recurrent miscarriages, and beneficial effect of metformin in these patients: a prospective clinical study. Fertil. Steril. 90, 727-730 (2007).
93. Gilbert C, Valois M, Koren G: Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. Fertil. Steril. 86, 658-663 (2006).
94. Jayagopal V, Kilpatrick ES, Holding S, Jennings PE, Atkin SL: Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 90, 729-733 (2005).
95. Luque CA, Rey JA: Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Ann. Pharmacother. 33, 968-978 (1999).
96. Sabuncu T, Harma M, Harma M, Nazligul Y, Kilic F: Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome. Fertil. Steril. 80, 1199-1204 (2003).
97. Florakis D, Diamanti-Kandarakis E, Katsikis I et al.: Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study. Int. J Obes. 32, 692-699 (2008).
98. Lindholm Å, Bixo M, Björn I et al.: Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Fertil. Steril. 89, 1221-1228 (2008).
99. Buchwald H, Avidor Y, Braunwald E et al.: Bariatric surgery: a systematic review and meta-analysis. JAMA 292, 1724-1737 (2004).
100. Sjöström L, Lindroos AK, Peltonen M et al.: Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N. Engl. J. Med. 351, 2683-2693 (2004).
101. Escobar-Morreale HF, Botella-Carretero JI, Álvarez-Blasco F, Sancho J, San Millán JL: The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. J. Clin. Endocrinol. Metab. 90, 6364-6369 (2005).
102. Eid GM, Cottam DR, Velcu LM et al.: Effective treatment of polycystic ovarian syndrome with Roux-en-Y gastric bypass. Surg. Obes. Relat. Dis. 1, 77-80 (2005).
103. Balen AH, Dresner M, Scott EM, Drife JO: Should obese women with polycystic ovary syndrome receive treatment for infertility? BMJ 332, 434-435 (2006).
104. Nelson SM, Fleming RF: The preconceptual contraception paradigm: obesity and infertility. Hum. Reprod. 22, 912-915 (2007).